Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Noninvasive Prenatal Screening Test Validated for Trisomies

By LabMedica International staff writers
Posted on 28 Oct 2015
Diagnosis of fetal aneuploidies relies on invasive testing by chorionic villous sampling (CVS) or amniocentesis in pregnancies that are identified by screening to be at high-risk for such aneuploidies.

A recently developed cell-free DNA (cfDNA) test which uses the Ion Proton sequencing platform and an algorithm that determines the relative number of chromosomal copies enabling detection of fetal trisomies has been assessed. More...


Scientists at King's College Hospital (London, UK) carried out a nested case-control study of stored maternal plasma from 242 singleton pregnancies at 11 to13 weeks’ gestation, including 201 with euploid fetuses, 35 with Down's syndrome (trisomy 21), 4 with Edwards' syndrome (trisomy 18), and 2 with Patau's syndrome (trisomy 13). A non-invasive prenatal screening test (NIPT) was used to analyze the blood samples.

The samples were analyzed with the IONA test and IONA Software (Premaitha Health plc; Manchester, UK). All 242 samples were processed with the IONA test that measures the relative amount of chromosomes 21, 18, and 13 in the maternal plasma sample to calculate a likelihood ratio to predict the presence of a trisomy. This data is coupled with the background risk associated with maternal age to determine an adjusted probability of the fetus having a trisomy of chromosome 21, 18, or 13.

Of the 242 samples; 35 were trisomy 21, 4 were trisomy 18, and 2 were trisomy 13, and therefore the IONA test detected 100% of all trisomies. This nested case-control study has demonstrated that in pregnancies considered by the combined test to be at high-risk for trisomies 21, 18, or 13, cfDNA testing of maternal plasma at 11 to 13 weeks’ gestation by the IONA test and IONA software, correctly identified all trisomic pregnancies with no false positives.

William Denman, MD, chief medical officer at Premaitha, said, “These results confirm what our customers have already reported; that the IONA test is a highly accurate, robust and simple screen for Down's syndrome and other serious genetic conditions. It is a great endorsement of the test that a scientific team has chosen to verify it. We believe this should encourage broader and appropriate uptake of NIPT, benefiting pregnant women and their families through the increased accuracy, especially the reduction in false positive results that the IONA test provides.” The study was published online on September 21, 2015, in the Journal of Ultrasound in Obstetrics and Gynaecology.

Related Links:

King's College Hospital 
Premaitha Health plc 



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.